JP2021523200A5 - - Google Patents

Info

Publication number
JP2021523200A5
JP2021523200A5 JP2020564158A JP2020564158A JP2021523200A5 JP 2021523200 A5 JP2021523200 A5 JP 2021523200A5 JP 2020564158 A JP2020564158 A JP 2020564158A JP 2020564158 A JP2020564158 A JP 2020564158A JP 2021523200 A5 JP2021523200 A5 JP 2021523200A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020564158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032289 external-priority patent/WO2019222266A1/en
Publication of JP2021523200A publication Critical patent/JP2021523200A/ja
Publication of JP2021523200A5 publication Critical patent/JP2021523200A5/ja
Ceased legal-status Critical Current

Links

JP2020564158A 2018-05-15 2019-05-14 Magl阻害剤 Ceased JP2021523200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671985P 2018-05-15 2018-05-15
US62/671,985 2018-05-15
PCT/US2019/032289 WO2019222266A1 (en) 2018-05-15 2019-05-14 Magl inhibitors

Publications (2)

Publication Number Publication Date
JP2021523200A JP2021523200A (ja) 2021-09-02
JP2021523200A5 true JP2021523200A5 (enExample) 2022-06-01

Family

ID=68534223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564158A Ceased JP2021523200A (ja) 2018-05-15 2019-05-14 Magl阻害剤

Country Status (25)

Country Link
US (3) US10570106B2 (enExample)
EP (1) EP3793547A4 (enExample)
JP (1) JP2021523200A (enExample)
KR (1) KR20210010475A (enExample)
CN (1) CN112088001A (enExample)
AR (1) AR115092A1 (enExample)
AU (1) AU2019271123A1 (enExample)
BR (1) BR112020000863A2 (enExample)
CA (1) CA3097063A1 (enExample)
CL (1) CL2020002927A1 (enExample)
CO (1) CO2020013550A2 (enExample)
CR (1) CR20200545A (enExample)
DO (1) DOP2020000207A (enExample)
EA (1) EA202092586A1 (enExample)
GE (2) GEP20227443B (enExample)
JO (1) JOP20200276A1 (enExample)
MA (1) MA52635A (enExample)
MX (1) MX2020012158A (enExample)
NI (1) NI202000080A (enExample)
PE (1) PE20211385A1 (enExample)
PH (1) PH12020551934A1 (enExample)
SG (1) SG11202011228TA (enExample)
TW (1) TW201946906A (enExample)
WO (1) WO2019222266A1 (enExample)
ZA (1) ZA202006327B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター,インク. ピペラジンカルバメート、及びその製造と使用の方法
KR102551319B1 (ko) 2018-05-14 2023-07-05 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
CA3096777A1 (en) 2018-06-27 2020-02-02 F. Hoffmann-La Roche Ag Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ. ホフマン-ラ ロシュ アーゲー カンナビノイド受容体2の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
MA54827A (fr) * 2019-01-25 2022-05-04 H Lundbeck As Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220101095A (ko) * 2019-11-15 2022-07-19 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
WO2022108984A1 (en) 2020-11-19 2022-05-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
EP4198023A1 (en) 2021-12-16 2023-06-21 Basf Se Pesticidally active thiosemicarbazone compounds
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US20250197358A1 (en) 2022-02-17 2025-06-19 Basf Se Pesticidally active thiosemicarbazone compounds
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
WO1993011097A1 (en) 1991-11-27 1993-06-10 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
WO1995017439A2 (en) 1993-12-22 1995-06-29 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
TW200531694A (en) 2004-02-18 2005-10-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
NZ590148A (en) 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびgpcrモジュレーターとしてのその使用
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 a 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
WO2011054795A1 (de) 2009-11-03 2011-05-12 Bayer Materialscience Ag Fluorurethane als additive in einer photopolymer-formulierung
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
PE20142098A1 (es) 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
ES2878041T3 (es) * 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター,インク. ピペラジンカルバメート、及びその製造と使用の方法
DK3541807T3 (da) * 2016-11-16 2021-12-06 H Lundbeck As Krystallinsk form af en magl-inhibitor
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
MA54827A (fr) 2019-01-25 2022-05-04 H Lundbeck As Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl

Similar Documents

Publication Publication Date Title
JP2021523200A5 (enExample)
JP2024514837A5 (enExample)
RU2019116512A (ru) Ингибиторы magl
JP2021514001A5 (enExample)
JP2020169171A5 (enExample)
JP2024050527A5 (enExample)
RU2019116514A (ru) Ингибиторы magl
JP2020521767A5 (enExample)
JP2019531279A5 (enExample)
JP2020529994A5 (enExample)
JP2020502047A5 (enExample)
JP2008510770A5 (enExample)
JP2016515096A5 (enExample)
JP2021527126A5 (enExample)
JP2020532545A5 (enExample)
JP2016534148A5 (enExample)
JP2018504437A5 (enExample)
JP2015532295A5 (enExample)
JP2019524883A5 (enExample)
JP2020511536A5 (enExample)
JP2022529311A5 (enExample)
JP2017508816A5 (enExample)
JP2022141692A5 (enExample)
JP2023518044A5 (enExample)
JP2020504184A5 (enExample)